Cargando…

Metabolic syndrome is an independent risk factor for time to complete remission of fertility-sparing treatment in atypical endometrial hyperplasia and early endometrial carcinoma patients

OBJECTIVE: Fertility-sparing treatment of atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EC) patients has recently emerged important social health topic. This study is designed to explore the risk factors for time to complete remission (CR) of fertility-sparing treatment in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Yingqiao, Fan, Yuan, Li, Xingchen, Wang, Yiqin, Wang, Jianliu, Tian, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442985/
https://www.ncbi.nlm.nih.gov/pubmed/36064542
http://dx.doi.org/10.1186/s12958-022-01006-0
_version_ 1784782943939461120
author Ding, Yingqiao
Fan, Yuan
Li, Xingchen
Wang, Yiqin
Wang, Jianliu
Tian, Li
author_facet Ding, Yingqiao
Fan, Yuan
Li, Xingchen
Wang, Yiqin
Wang, Jianliu
Tian, Li
author_sort Ding, Yingqiao
collection PubMed
description OBJECTIVE: Fertility-sparing treatment of atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EC) patients has recently emerged important social health topic. This study is designed to explore the risk factors for time to complete remission (CR) of fertility-sparing treatment in woman with AEH and early EC. METHODS: A retrospective study was designed with clinical data from 106 patients admitted between January 2012 to December 2019. Univariate and multivariate logistic analysis were used to explore independent risk factors for time to CR. These factors were employed in receiver operator characteristic (ROC) curve and the decision curve analysis (DCA) to evaluate predictive accuracy of time to CR. Stratified analysis and interactive analysis was also performed for more in-depth perspective. RESULTS: Univariate analysis showed that fasting blood glucose levels (FBG, OR = 1.6, 95%CI: 0.6–2.5, P = 0.020), metabolic syndrome (MetS, OR = 3.0, 95%CI: 1.1–5.0, P = 0.003), and polycystic ovary syndrome (PCOS, OR = 2.0, 95%CI: 0.5–3.4, P = 0.009) were associated with time to CR. Among these factors, multivariate analysis confirmed MetS (OR = 3.1, 95%CI: 1.0–5.2, P = 0.005) was an independent risk factor. The area under the ROC curve (AUC) of MetS was higher than FBG and PCOS (AUC = 0.723 vs 0.612 and 0.692). The AUC of FBG combined with PCOS was 0.779, and it was improved to 0.840 when MetS was included (P < 0.05). Additionally, MetS played different roles in time to CR in various groups. Moreover, we found high-density lipoprotein (HDL) and MetS had an interactive effect for time to CR. CONCLUSION: MetS is an independent risk factor for time to CR and should be taken seriously in fertility-sparing management of AEH and early EC patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12958-022-01006-0.
format Online
Article
Text
id pubmed-9442985
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94429852022-09-06 Metabolic syndrome is an independent risk factor for time to complete remission of fertility-sparing treatment in atypical endometrial hyperplasia and early endometrial carcinoma patients Ding, Yingqiao Fan, Yuan Li, Xingchen Wang, Yiqin Wang, Jianliu Tian, Li Reprod Biol Endocrinol Research OBJECTIVE: Fertility-sparing treatment of atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EC) patients has recently emerged important social health topic. This study is designed to explore the risk factors for time to complete remission (CR) of fertility-sparing treatment in woman with AEH and early EC. METHODS: A retrospective study was designed with clinical data from 106 patients admitted between January 2012 to December 2019. Univariate and multivariate logistic analysis were used to explore independent risk factors for time to CR. These factors were employed in receiver operator characteristic (ROC) curve and the decision curve analysis (DCA) to evaluate predictive accuracy of time to CR. Stratified analysis and interactive analysis was also performed for more in-depth perspective. RESULTS: Univariate analysis showed that fasting blood glucose levels (FBG, OR = 1.6, 95%CI: 0.6–2.5, P = 0.020), metabolic syndrome (MetS, OR = 3.0, 95%CI: 1.1–5.0, P = 0.003), and polycystic ovary syndrome (PCOS, OR = 2.0, 95%CI: 0.5–3.4, P = 0.009) were associated with time to CR. Among these factors, multivariate analysis confirmed MetS (OR = 3.1, 95%CI: 1.0–5.2, P = 0.005) was an independent risk factor. The area under the ROC curve (AUC) of MetS was higher than FBG and PCOS (AUC = 0.723 vs 0.612 and 0.692). The AUC of FBG combined with PCOS was 0.779, and it was improved to 0.840 when MetS was included (P < 0.05). Additionally, MetS played different roles in time to CR in various groups. Moreover, we found high-density lipoprotein (HDL) and MetS had an interactive effect for time to CR. CONCLUSION: MetS is an independent risk factor for time to CR and should be taken seriously in fertility-sparing management of AEH and early EC patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12958-022-01006-0. BioMed Central 2022-09-05 /pmc/articles/PMC9442985/ /pubmed/36064542 http://dx.doi.org/10.1186/s12958-022-01006-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ding, Yingqiao
Fan, Yuan
Li, Xingchen
Wang, Yiqin
Wang, Jianliu
Tian, Li
Metabolic syndrome is an independent risk factor for time to complete remission of fertility-sparing treatment in atypical endometrial hyperplasia and early endometrial carcinoma patients
title Metabolic syndrome is an independent risk factor for time to complete remission of fertility-sparing treatment in atypical endometrial hyperplasia and early endometrial carcinoma patients
title_full Metabolic syndrome is an independent risk factor for time to complete remission of fertility-sparing treatment in atypical endometrial hyperplasia and early endometrial carcinoma patients
title_fullStr Metabolic syndrome is an independent risk factor for time to complete remission of fertility-sparing treatment in atypical endometrial hyperplasia and early endometrial carcinoma patients
title_full_unstemmed Metabolic syndrome is an independent risk factor for time to complete remission of fertility-sparing treatment in atypical endometrial hyperplasia and early endometrial carcinoma patients
title_short Metabolic syndrome is an independent risk factor for time to complete remission of fertility-sparing treatment in atypical endometrial hyperplasia and early endometrial carcinoma patients
title_sort metabolic syndrome is an independent risk factor for time to complete remission of fertility-sparing treatment in atypical endometrial hyperplasia and early endometrial carcinoma patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442985/
https://www.ncbi.nlm.nih.gov/pubmed/36064542
http://dx.doi.org/10.1186/s12958-022-01006-0
work_keys_str_mv AT dingyingqiao metabolicsyndromeisanindependentriskfactorfortimetocompleteremissionoffertilitysparingtreatmentinatypicalendometrialhyperplasiaandearlyendometrialcarcinomapatients
AT fanyuan metabolicsyndromeisanindependentriskfactorfortimetocompleteremissionoffertilitysparingtreatmentinatypicalendometrialhyperplasiaandearlyendometrialcarcinomapatients
AT lixingchen metabolicsyndromeisanindependentriskfactorfortimetocompleteremissionoffertilitysparingtreatmentinatypicalendometrialhyperplasiaandearlyendometrialcarcinomapatients
AT wangyiqin metabolicsyndromeisanindependentriskfactorfortimetocompleteremissionoffertilitysparingtreatmentinatypicalendometrialhyperplasiaandearlyendometrialcarcinomapatients
AT wangjianliu metabolicsyndromeisanindependentriskfactorfortimetocompleteremissionoffertilitysparingtreatmentinatypicalendometrialhyperplasiaandearlyendometrialcarcinomapatients
AT tianli metabolicsyndromeisanindependentriskfactorfortimetocompleteremissionoffertilitysparingtreatmentinatypicalendometrialhyperplasiaandearlyendometrialcarcinomapatients